FDA bestows accelerated approval on ImmunoGen's ovarian cancer drug, with confirmatory answer coming soon

Three and a half years ago, ImmunoGen ran up against an FDA brick wall. Its ovarian cancer drug, mirvetuximab soravtansine, failed a Phase III …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA be­stows ac­cel­er­at­ed ap­proval on Im­muno­Gen's ovar­i­an can­cer drug, with con­fir­ma­to­ry an­swer com­ing soon